Table 1.
Baseline characteristics of individuals receiving prophylactic LMWH and those not receiving prophylactic anticoagulation for the capital regions of Denmark and Sweden
| Denmark |
Sweden |
|||||
|---|---|---|---|---|---|---|
| Prophylactic LMWH, n (%) |
No anticoagulation, n (%) |
Missing, % | Prophylactic LMWH, n (%) |
No anticoagulation, n (%) |
Missing, % | |
| (N = 771) | (N = 921) | (N = 1167) | (N = 701) | |||
| Demographics | ||||||
| Age, median [IQR] | 72 [59, 82] | 72 [56, 81] | — | 60 [47, 73] | 55 [36, 70] | — |
| Male sex | 412 (53) | 465 (50) | — | 658 (56) | 349 (50) | — |
| Time period | — | — | ||||
| Before June 2020 | 94 (12) | 525 (57) | 414 (36) | 363 (52) | ||
| June to October 2020 | 119 (15) | 74 (8) | 122 (11) | 94 (13) | ||
| November 2020 to February 2021 | 558 (72) | 322 (35) | 383 (33) | 149 (21) | ||
| March to June 2021 | — | — | 216 (19) | 90 (13) | ||
| July 2021 to August 2021 | — | — | 32 (3) | 5 (1) | ||
| Clinical measurements | ||||||
| Body mass index | 16 | 50 | ||||
| <18.5 | 34 (5) | 31 (4) | 22 (4) | 8 (3) | ||
| 18.5-24 | 230 (34) | 256 (35) | 203 (33) | 133 (41) | ||
| 25-34 | 343 (51) | 398 (54) | 366 (59) | 163 (51) | ||
| 35+ | 69 (10) | 56 (8) | 30 (5) | 17 (5) | ||
| Smoking history | 29 | 100 | ||||
| Ex-smoker | 287 (53) | 299 (45) | — | — | ||
| Current smoker | 55 (10) | 70 (10) | — | — | ||
| Body temperature, C | <1 | 9 | ||||
| 37.5-38.4 | 219 (28) | 266 (29) | 353 (31) | 165 (29) | ||
| 38.5+ | 194 (25) | 192 (21) | 358 (32) | 115 (20) | ||
| Respiratory frequency/min >22 | 305 (40) | 280 (31) | <1 | 526 (47) | 215 (38) | 9 |
| Systolic blood pressure <100 mmHg | 26 (3) | 42 (5) | <1 | 41 (4) | 22 (4) | 9 |
| Reduced peripheral oxygen saturation, % | 7 | 16 | ||||
| <88 | 40 (5) | 15 (2) | 56 (5) | 27 (5) | ||
| 88-92 | 122 (17) | 100 (12) | 199 (19) | 65 (13) | ||
| Oxygen therapy, l/min | 3 | 11 | ||||
| 1-4 | 280 (37) | 200 (23) | 443 (40) | 139 (25) | ||
| 5+ | 76 (10) | 51 (6) | 104 (9) | 33 (6) | ||
| Biochemical measurements | ||||||
| Estimated GFR l/min/1.73m2 | 3 | 10 | ||||
| 30-59 | 101 (13) | 119 (13) | 192 (17) | 115 (20) | ||
| 15-29 | 37 (5) | 36 (4) | 51 (5) | 35 (6) | ||
| <15 | 11 (1) | 8 (1) | 21 (2) | 8 (1) | ||
| Haemoglobin below reference | 289 (38) | 335 (37) | 2 | 333 (30) | 186 (32) | 9 |
| Leukocyte levels | 3 | 8 | ||||
| Below reference | 183 (24) | 226 (25) | 81 (7) | 51 (9) | ||
| Above reference | 49 (6) | 52 (6) | 214 (19) | 174 (29) | ||
| Thrombocyte levels | 3 | 9 | ||||
| Below reference | 100 (13) | 130 (15) | 175 (16) | 93 (16) | ||
| Above reference | 76 (10) | 84 (10) | 54 (5) | 22 (4) | ||
| Elevated D-dimer∗ | 355 (66) | 323 (67) | 40 | 704 (72) | 234 (70) | 30 |
| Prescription drug use prior to hospitalisation | ||||||
| Platelet inhibitors | 193 (25) | 226 (25) | — | 125 (11) | 71 (10) | — |
| Antihypertensives | 346 (45) | 400 (43) | — | 312 (27) | 175 (25) | — |
| Loop diuretics | 115 (15) | 116 (13) | — | 89 (8) | 69 (10) | — |
| Glucose lowering therapy | 176 (23) | 171 (19) | — | 206 (18) | 111 (16) | — |
| Lipid lowering therapy | 235 (30) | 273 (30) | — | 189 (16) | 84 (12) | — |
| Glucocorticoids | 191 (25) | 91 (10) | — | 277 (24) | 122 (17) | — |
| In-hospital dexa-/betamethasone treatment | 505 (65) | 158 (17) | — | 381 (33) | 108 (15) | — |
| Medical history | ||||||
| VTE | 6 (1) | 11 (1) | — | — | — | — |
| Atrial fibrillation | 15 (2) | 31 (3) | — | 12 (1) | 15 (2) | — |
| Heart valve disease | 34 (4) | 39 (4) | — | 15 (1) | 16 (2) | — |
| Cardiovascular disease | 188 (24) | 204 (22) | — | 165 (14) | 95 (14) | — |
| Heart failure | 57 (7) | 55 (6) | — | 56 (5) | 38 (5) | — |
| Ischaemic stroke | 58 (8) | 66 (7) | — | 28 (2) | 21 (3) | — |
| Current cancer | 76 (10) | 81 (9) | — | 90 (8) | 73 (10) | — |
| Pulmonary disease | 172 (22) | 185 (20) | — | 140 (12) | 71 (10) | — |
| Liver disease | 15 (2) | 20 (2) | — | 39 (3) | 27 (4) | — |
LMWH: Low molecular weight heparin; GFR: Glomerular filtration rate; VTE: Venous thromboembolism; IQR: Interquartile range.
∗
Age-specific cut-offs between 0.5 and 0.8 FEU/l.